Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Oral Potentially Malignant Disorders and Oral Cavity Cancer
share announcement

Oral Potentially Malignant Disorders and Oral Cavity Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 31 March 2025 | Viewed by 3419

Special Issue Editor

Dr. I-Ta Lee

E-Mail Website
Guest Editor
School of Dentistry, College of Oral Medicine, Taipei Medical University, Taipei 110301, Taiwan
Interests: signaling transduction; inflammation; cancer; antioxidants; anti-inflammation; anti-cancer
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue in the journal Cancers is dedicated to the in-depth exploration of oral potentially malignant disorders (OPMDs) and oral cavity cancer, focusing on clinical, molecular, and translational aspects. We invite contributions from experts in the field, covering topics such as the clinical characteristics, pathology, molecular biology, and genomics of OPMDs. This Special Issue emphasizes key events in the transition of OPMDs to oral cavity cancer, with a particular focus on gene variations, protein abnormalities, and cellular signaling pathways associated with pathogenesis. Additionally, we welcome research on novel diagnostic tools, imaging techniques, and therapeutic strategies to enhance the precision of early detection and treatment. This Special Issue seeks contributions that provide new insights and approaches to the treatment of OPMDs and oral cavity cancer, including advancements in personalized therapy, immunotherapy, and targeted treatments. Ultimately, we aim to advance a more comprehensive and in-depth understanding of these disorders, fostering translational medicine and precision healthcare in clinical practice.

In this Special Issue, we enthusiastically invite the submission of original research articles and reviews. We welcome contributions across a broad spectrum of research areas, including but not limited to the following:

  • Clinical characteristics of oral potentially malignant disorders (OPMDs);
  • Molecular mechanisms underlying the progression of OPMDs to oral cavity cancer;
  • Advances in diagnostic imaging technologies for early detection;
  • Biomarkers for predicting the risk and progression of oral cavity cancer;
  • Therapeutic approaches and novel interventions for OPMDs and oral cavity cancer;
  • Genomic and proteomic studies informing precision medicine in oral oncology;
  • Immunotherapeutic strategies and immune microenvironment in oral cavity tumors;
  • Translational research bridging bench to bedside in oral cancer;
  • Patient stratification and personalized treatment plans;
  • Emerging trends and future perspectives in oral oncology research.

We look forward to receiving your valuable contributions to this Special Issue.

Dr. I-Ta Lee
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • OPMDs
  • oral cavity cancer
  • molecular biology
  • genomics
  • pathology
  • early detection
  • personalized therapy
  • immunotherapy
  • targeted treatment
  • translational medicine

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

10 pages, 1222 KiB  
Article
Association between Periodontitis and Hematologic Cancer: An NHIRD Cohort Study in Taiwan
by Liang-Gie Huang, Cheng-Chia Yu, Ming-Ching Lin, Yu-Hsun Wang and Yu-Chao Chang
Cancers 2024, 16(9), 1671; https://doi.org/10.3390/cancers16091671 - 25 Apr 2024
Cited by 1 | Viewed by 1311
Abstract
Background: Chronic periodontitis, an inflammation-related disorder affecting global populations, has been revealed to be linked to diverse cancers. Numerous epidemiological studies have not shown a link between chronic periodontitis and blood cancers in Taiwan. Methods: This study included 601,628 patients, diagnosed with newly [...] Read more.
Background: Chronic periodontitis, an inflammation-related disorder affecting global populations, has been revealed to be linked to diverse cancers. Numerous epidemiological studies have not shown a link between chronic periodontitis and blood cancers in Taiwan. Methods: This study included 601,628 patients, diagnosed with newly chronic periodontitis by the ICD-9-CM classification, who were enrolled from 2001 to 2021 in the National Health Insurance Research Database (NHIRD) in Taiwan. In this study, we employed comprehensive statistical analyses to investigate the association between chronic periodontitis and hematologic cancers. Initially, we calculated incidence density and used a Poisson regression to analyze relative risk. Subsequently, we compared the cumulative incidence of hematological cancer in both chronic and non-chronic periodontitis groups using the Kaplan–Meier method. Results: The results revealed a significantly lower cumulative incidence of hematologic cancer in individuals with non-chronic periodontitis over a 12-year follow-up period. To further explore the risk factors, a Cox proportional hazard regression analysis was conducted. Being male (adjusted hazard ratio [aHR] = 1.21, 95% CI: 1.04 to 1.42; p = 0.014) and having hypertension (aHR = 1.34, 95% CI: 1.06 to 1.69; p = 0.015) were demonstrated to be associated with an increased risk of hematologic cancers, respectively. In addition, in a subtype multivariate analysis for categorizing hematologic cancers into lymphoma and leukemia, the aHR for leukemia was 1.48 (95% CI: 1.13 to 1.93; p = 0.004) and aHR for lymphoma was 1.15 (95% CI: 0.96 to 1.37; p = 0.140). Conclusions: This study found that being male and having hypertension were the significant risk factors for hematological malignancies. Moreover, the association between chronic periodontitis and specific subtypes of hematologic cancers was confirmed. Full article
(This article belongs to the Special Issue Oral Potentially Malignant Disorders and Oral Cavity Cancer)
►▼ Show Figures

Figure 1

Review

Jump to: Research

19 pages, 335 KiB  
Review
A Narrative Review: Repurposing Metformin as a Potential Therapeutic Agent for Oral Cancer
by Jui-Hsiang Li, Pei-Yi Hsin, Yung-Chia Hsiao, Bo-Jun Chen, Zhi-Yun Zhuang, Chiang-Wen Lee, Wei-Ju Lee, Thi Thuy Tien Vo, Chien-Fu Tseng, Shih-Fen Tseng and I-Ta Lee
Cancers 2024, 16(17), 3017; https://doi.org/10.3390/cancers16173017 - 29 Aug 2024
Viewed by 1000
Abstract
Oral cancer, particularly oral squamous cell carcinoma (OSCC), is a significant global health challenge because of its high incidence and limited treatment options. Major risk factors, including tobacco use, alcohol consumption, and specific microbiota, contribute to the disease’s prevalence. Recently, a compelling association [...] Read more.
Oral cancer, particularly oral squamous cell carcinoma (OSCC), is a significant global health challenge because of its high incidence and limited treatment options. Major risk factors, including tobacco use, alcohol consumption, and specific microbiota, contribute to the disease’s prevalence. Recently, a compelling association between diabetes mellitus (DM) and oral cancer has been identified, with metformin, a widely used antidiabetic drug, emerging as a potential therapeutic agent across various cancers, including OSCC. This review explores both preclinical and clinical studies to understand the mechanisms by which metformin may exert its anticancer effects, such as inhibiting cancer cell proliferation, inducing apoptosis, and enhancing the efficacy of existing treatments. Preclinical studies demonstrate that metformin modulates crucial metabolic pathways, reduces inflammation, and impacts cellular proliferation, thereby potentially lowering cancer risk and improving patient outcomes. Additionally, metformin’s ability to reverse epithelial-to-mesenchymal transition (EMT), regulate the LIN28/let-7 axis, and its therapeutic role in head and neck squamous cell carcinoma (HNSCC) are examined through experimental models. In clinical contexts, metformin shows promise in enhancing therapeutic outcomes and reducing recurrence rates, although challenges such as drug interactions, complex dosing regimens, and risks such as vitamin B12 deficiency remain. Future research should focus on optimizing metformin’s application, investigating its synergistic effects with other therapies, and conducting rigorous clinical trials to validate its efficacy in OSCC treatment. This dual exploration underscores metformin’s potential to play a transformative role in both diabetes management and cancer care, potentially revolutionizing oral cancer treatment strategies. Full article
(This article belongs to the Special Issue Oral Potentially Malignant Disorders and Oral Cavity Cancer)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop